Navigation Links
Infinata’s BioPharm Insight™ Achieves Record Growth in 2012
Date:2/4/2013

Norwood, MA (PRWEB) February 04, 2013

Infinata’s BioPharm Insight™ capped another year of global expansion in 2012. BioPharm Insight offers subscribers the unique combination of comprehensive market analytics, a database of key industry contacts and proprietary forward-looking intelligence uncovered by an independent team of investigative journalists.

Ruth McHenry, Managing Director of Infinata, said, “BioPharm Insight continues its aggressive growth to meet the needs of industry professionals. Every day we work closely with our customers to understand and solve the challenges they face. I am so proud to say that in 2012 we met and exceeded all targeted areas of growth.”

New Features & Functionalities

New User Interface – BioPharm Insight’s completely redesigned user interface (UI) features a customizable homepage, easier navigation, and interactive charts and graphs. These enhancements allow subscribers to filter data and intelligence to fit their needs, allowing them to identify business opportunities as soon as they arise.

Increased Scope of Data – In addition to a new UI, BioPharm Insight continued to improve the scope of data provided to subscribers with the addition of:

  •     SEC filings
  •     NIH grant data
  •     Medicaid data
  •     EudraCT studies (BioPharm Clinical™)
  •     Expected Catalysts Calendar – by compiling study start and end dates, patent expirations and commercial launches by forecasts, BioPharm Insight provides the most comprehensive calendar of upcoming catalysts.

Analytics – Last year BioPharm Insight added the following analytics to further improve subscribers’ ability to find and use data quickly and efficiently:

  •     CRO activity
    '/>"/>

Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Infinata's BioPharm Clinical™ to Present Session on Improving Investigator Selection at CHI’s Summit for Clinical Operations (SCOPE) on February 6 in Miami, FL
2. Sutro Biopharma Appoints Edward C. Albini as Chief Financial Officer
3. Array BioPharma To Report Financial Results For The Second Quarter Of Fiscal 2013 On February 4, 2013
4. BioPharm Systems to Host Webinar on an Add-On Solution for Oracle Clinical
5. BioPharm Systems to Host Webinar on Self-service Account Management for Oracle Clinical, Remote Data Capture, and Thesaurus Management System
6. Array BioPharma Provides Updates On Clinical Data At The 2012 American Society Of Hematology Meeting
7. TransCelerate BioPharma Inc. Appoints Dalvir Gill as Chief Executive Officer
8. Array BioPharma Announces Exercise And Closing Of Underwriters Over-Allotment Option
9. Gallus BioPharmaceuticals Announces Appointment of Senior Baxter Executive as Chief Commercial Officer
10. PDL BioPharma to Present at the Lazard Capital Markets 9th Annual Healthcare Conference
11. Keryx Biopharmaceuticals, Inc. Announces Third Quarter 2012 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... Based on the revenues gained ... market is dominated by four major players contributing ... These players include GE Healthcare (U.K.), Siemens AG ... , Full Report Copy at http://www.marketsandmarkets.com/Market-Reports/surgical-imaging-market-210534462.html ... be attributed to its strong product portfolio, which ...
(Date:12/17/2014)... Once more, EMAAR has selected BioShaft ... water treatment plant to phase one of BayLaSun, a ... years ago Bioshaft successfully supplied and operated a packaged ... towers with an occupancy of 900 residences. The ... per day and was signed on September 16th, 2014, ...
(Date:12/17/2014)... 17, 2014 Audacity, a leading California-based ... member of the Huntsworth Health Group, is proud to ... team. In her role, Gonzales will serve as Senior ... incredibly honored to welcome a talent of Jamie’s caliber ... Gaëtan Fraikin. “She is a proven healthcare innovation leader ...
(Date:12/17/2014)... FRANCISCO, Calif. , Dec. 17, 2014 /PRNewswire/ ... of a Phase 2 study evaluating the investigational ... treatment of patients with severe, chronic itch who ... standard of care, including topical steroids and antihistamines. ... percent change in Visual Analog Scale (VAS) itch ...
Breaking Biology Technology:Global Refurbished Surgical Imaging Market by Product & Application is Estimated to Reach $1.25 Billion by 2019 - New Research Report by MarketsandMarkets 2Global Refurbished Surgical Imaging Market by Product & Application is Estimated to Reach $1.25 Billion by 2019 - New Research Report by MarketsandMarkets 3Global Refurbished Surgical Imaging Market by Product & Application is Estimated to Reach $1.25 Billion by 2019 - New Research Report by MarketsandMarkets 4Audacity Welcomes Healthcare Communications Expert Jamie Gonzales as Senior Vice President of Client Services 2Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 2Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 3Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 4
... ANNAPOLIS, Md., May 8 PharmAthene, Inc. (NYSE Amex: ... countermeasures against biological and chemical threats, announced a date ... Company,s first quarter 2009 financial results will now be ... hosting a conference call to discuss its first quarter ...
... Biosolutions has announced that it will increase its C-Reactive ... Protein is a protein found in the blood that ... indicates an increased state of inflammation in the body. ... physical states including injury, fever and infection. Inflammation is ...
... host call and webcast today at 5:00 p.m. Eastern to ... , SAN DIEGO, May 7 Orexigen(R) Therapeutics, ... on the treatment of obesity, today announced unaudited financial results ... Months Ended March 31, 2009 , As of March ...
Cached Biology Technology:Orexigen(R) Therapeutics Announces First Quarter 2009 Financial Results 2Orexigen(R) Therapeutics Announces First Quarter 2009 Financial Results 3Orexigen(R) Therapeutics Announces First Quarter 2009 Financial Results 4Orexigen(R) Therapeutics Announces First Quarter 2009 Financial Results 5Orexigen(R) Therapeutics Announces First Quarter 2009 Financial Results 6Orexigen(R) Therapeutics Announces First Quarter 2009 Financial Results 7Orexigen(R) Therapeutics Announces First Quarter 2009 Financial Results 8Orexigen(R) Therapeutics Announces First Quarter 2009 Financial Results 9
(Date:12/10/2014)... 2014  Wake Forest Baptist Medical Center today announced plans ... of Medicine. Funding for this $50 million capital project ... be publicly launched next summer. The ... 60 series R.J. Reynolds Tobacco Company complex, adjacent to ... immediately with plans to be ready to welcome medical ...
(Date:12/5/2014)... -- Tute Genomics, a leader in cloud-based solutions for genome ... led by UK-based Eurovestech. Peak Ventures and a number ... "We are at a pivotal time in ... seeks new approaches for the diagnosis, treatment and prevention ... and CEO of Tute Genomics. "One of the main ...
(Date:11/21/2014)... 19, 2014  Earlier this year Donald Spector ... and one of the most prolific inventors in the ... transmitted from Smartphones to third party agencies. Spector envisioned ... one of the earliest known patents in this area. ... the military, child care, elder care and hospital applications. ...
Breaking Biology News(10 mins):Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 2Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 3Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 4Tute Genomics Raises $2.3 Million to Scale Up Cloud-Based Genome Analytics and Accelerate Personalized Medicine 2Tute Genomics Raises $2.3 Million to Scale Up Cloud-Based Genome Analytics and Accelerate Personalized Medicine 3Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 2Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 3Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 4
... article in Environmental Microbiology reveals that indigenous microbiota ... degrade crude oil. Scientists from the Estación Experimental ... Granada investigated in situ crude oil degradation after ... After a spill, hydrocarbons are subjected to physicochemical ...
... cancer of the mouth and throat, surgery is ... speech and swallowing dysfunction and external scarring. Researchers ... Department of Otorhinolaryngology/Head and Neck Surgery, have completed ... date ?that demonstrate the effective use of the ...
... advising breastfeeding moms that alcoholic beverages can improve their ... report that even moderate doses of alcohol affect the ... "This information is important for women," comments lead author ... drinking alcohol just to improve the quality or quantity ...
Cached Biology News:A hope for oil spill bioremediation 2Two new retroviruses—transmitted from animals—identified 2Two new retroviruses—transmitted from animals—identified 3Alcohol consumption disrupts breastfeeding hormones 2Alcohol consumption disrupts breastfeeding hormones 3
Mouse Wnt-9b Affinity Purified Polyclonal Ab Keywords: Wnt 9b Protein Family: Cancer Stem Cell Markers, Wnt Ligands...
One-step, microplate or cuvet, colorimetric, linear detection range 0.6 mM to 100 mM. Procedure: 2 min....
One-step, microplate or cuvet, colorimetric, linear detection range 6 mg/dL to 100mg/dL. Procedure: 15 min....
assays for phosphatase, lipase, nucleoside triphosphatases (ATPase, GTPase etc). HTS and follow up studies for phosphatase inhibitors. Quantitation of phosphate content in protein, lipids, and DNA....
Biology Products: